The UN Sustainable Development Goals (SDGs) set out a vision for ending poverty, hunger, inequality and protecting the Earth’s natural resources by 2030. Realising this ambition will require private sector, governments and civil society to play their part and work together in new and innovative ways.
As a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines, Goal 3 “Good health and wellbeing” is where we can make the most important contribution. In total we have identified 7 out of the 17 SDGs as being most material to our business and the products and services we provide to our stakeholders. These are:
In February 2021, we conducted an initial materiality assessment to support our understanding of major ESG issues that may impact our business, both now and in the future. The assessment has supported us in identifying where we believe we have the greatest opportunity to address and minimise our impacts across the ESG agenda. A summary of our materiality assessment can be found here.
It should be noted that we fully subscribe to the objectives of the 17 goals. The materiality assessment has enabled us to identify where we can contribute and have the biggest impact. On an annual basis we will report how we have contributed to these SDGs, including our activities, impacts and targets.
We have shown below how each of our four pillars and individual commitments map to the SDGs we can make the most important contribution towards: